EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes

Qiumei Zhang, Yaqing Fan, Xixi Liu, Minlu Zhang, Jiewen Zhang, Qin Du, Lei Kang, Liming Chen iD

Journal of Diabetes Investigation · 2025

DOI: 10.1111/jdi.14415 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Diabetes Investigation, 2025. Verfasst von Qiumei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glycemic Control, Insulin. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi China Investment Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China. Materials and methods Data from inpatients and outpatients receiving injectable therapies between January 2015 and December 2019 were collected from the Tianjin regional electronic medical records and retrospectively analyzed. Seven cohorts were identified, including individuals initiating injectable therapies (premixed insulin [ n = 4,687], basal insulin [4,177], or glucagon‐like peptide‐1 receptor agonists [541]) or switching injectable therapies (premixed insulin to basal insulin [1,298], basal insulin to premixed insulin [1,457], basal insulin to basal + bolus insulin [1,772], or glucagon‐like peptide‐1 receptor agonists to basal insulin ± glucagon‐like peptide‐1 receptor agonists [82]).

Results

In participants initiating therapy, glycated hemoglobin and fasting plasma glucose were highest in the basal insulin cohort, while among participants switching therapy, the highest values were in the basal insulin ± glucagon‐like peptide‐1 receptor agonists cohort. Initiating therapy with premixed or basal insulin and switching from basal insulin to basal + bolus insulin improved glycemic control over 12 months. A mean delay in initiating therapy of up to 13 months after oral glucose‐lowering drug failure was observed, with 60% having a delay of >6 months. This delay was associated with a lower proportion achieving glycemic control 3 months after initiation.

Conclusions

Effectiveness was not observed at all time points in all cohorts, suggesting some treatments were not used in the appropriate population. Delays in initiating injectable therapies were observed and were associated with poor glycemic control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlycemic ControlInsulinHumansRetrospective StudiesMaleFemaleMiddle AgedChinaBlood GlucoseAgedGlycated HemoglobinAdultInjectionsGlucagon-Like Peptide-1 Receptor AgonistsFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

Glucagon‐like peptide‐1 receptor agonistsHypoglycemic agentsInsulins

Substanzen

Hypoglycemic AgentsBlood GlucoseGlycated HemoglobinInsulinhemoglobin A1c protein, humanGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
  • Sanofi Investment Co., Ltd., Shanghai, China.

ORCID-Profile: Liming Chen

Förderung

  • Sanofi China Investment Company

Zitieren

APA

Zhang, Q., Fan, Y., Liu, X., Zhang, M., Zhang, J., Du, Q., Kang, L., & Chen, L. (2025). Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14415

Vancouver

Zhang Q, Fan Y, Liu X, Zhang M, Zhang J, Du Q, et al. Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes. Journal of Diabetes Investigation. 2025. doi:10.1111/jdi.14415

BibTeX
@article{Zhang2025,
  author = {Zhang, Qiumei and Fan, Yaqing and Liu, Xixi and Zhang, Minlu and Zhang, Jiewen and Du, Qin and Kang, Lei and Chen, Liming},
  title = {Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes},
  journal = {Journal of Diabetes Investigation},
  year = {2025},
  doi = {10.1111/jdi.14415}
}
Kostenlos starten →